KIT and thymic carcinoma: KIT-mutant thymic carcinomas represent a small—9% of cases in our study—molecular subset of thymic carcinomas.8 The relevance of those mutations as a therapeutic target remains challenging as non-pretreated KIT mutants may not be uniformly sensitive to available KIT inhibitors, based on the clinical and/or the preclinical evidence in thymic carcinoma and/or other KIT-mutant tumors (https://www.mycancergenome.org/content/disease/thymic-carcinoma/).